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We hypothesize that AMD3100 creates space within the endogenous
stem cell niche allowing for better engraftment of transplanted HSC
donors.
We found that subcutaneous injections of AMD3100 (5mg/kg)
into C57/BL6-Rag2 common gamma chain-deficient mice induced
mobilization of HSCs from bone marrow and absolute numbers of
HSC in bone marrow reached a nadir four hours post-AMD3100 in-
jection (20136553 vs. 37656392, p 5 0.02, n 5 4-6). AMD3100
pre-treated immunodeficient recipients were transplanted with a bo-
lus dose of 6300 MHC-mismatched AKR/j HSCs. We also per-
formed daily rounds of AMD3100 injections followed by low dose
injections of 450 HSCs over the course of 14 days for a total trans-
plant of 6300 cells. HSC bone marrow donor chimerism 12-weeks
post-transplant was not increased in the bolus-transplanted animals
(1.960.6% vs. 1.460.3%, p5 0.7, n5 5-9). Repeat-transplanted an-
imals exhibited a slight increase in engraftment; however, this in-
crease was not found to be statically significant (2.160.2% vs.
2.560.8%, p 5 0.4, n 5 4-5). These data demonstrate that while
AMD3100 is effective as a HSC mobilizer, it is not effective in
increasing engraftment potential of transplant recipients.421
USE OF UMBILICAL CORD BLOOD IN TRANSPLANTATION FOR PATIENTS
WITH MYELODYSPLASTIC SYNDROME
Bhatla, D.1,Wofford, J.D.2, Regan, D.M.2 1St. Louis University School of
Medicine, St. Louis, MO; 2SSM Cardinal Glennon Children’s Medical
Center, St. Louis, MO
Myelodysplastic Syndrome is a clonal hematological disorder
characterized by peripheral cytopenias with significant risk for pro-
gression to acute myeloid leukemia (AML). It is the most common
hematological malignancy in the elderly with 86% of all MDS diag-
noses reported in individuals over 60 years of age, according to
SEER data. While hypomethylating agents may delay disease pro-
gression and extend overall survival in low riskMDS patients, alloge-
neic hematopoietic stem cell transplant is the only potentially
curative therapy for high risk MDS. The use of umbilical cord blood
as a stem cell source forMDSpatients is attractive because of rapidity
of availability as well as the lower risk of GVHD with increasing
HLA disparity. Outcomes data is limited, but encouraging results
have been reported. This study seeks to examine transplant outcomesTable 1. Data Summary – Single and Dual Cord Blood Trans-
plants








Yes 24 (100%) 19 (86.4%)
No 0 (0%) 3 (13.6%)
Days to ANC Achieved
Mean 23.3 24.0
Acute GVHD
Yes 17 (70.8%) 4 (18.2%)
No 7 (29.2%) 6 (27.3%)
Unknown 0 (0%) 12 (54.5%)
Chronic GVHD
Yes 6 (25%) 1 (4.5%)
No 16 (66.7%) 8 (36.4%)
Unknown 2 (8.3%) 13 (59.1%)
Survival
Alive 17 (70.8%) 11 (50%)
Expired 7 (29.2%) 11 (50%)
Mean Survival (months) 23.1 11.2of MDS patients receiving umbilical cord blood units from the St.
Louis Cord Blood Bank (SLCBB).
As of September 30, 2010, the SLCBB has shipped units for 95
MDS patients, of which outcomes data is available for 46. Summary
data is provided in the table below for single and dual cord
transplants: Umbilical cord blood is a viable source of stem cells
for HSCT in MDS patients. More data will be required to examine
a possible risk of increased graft vs. host disease with this population.422
KILLER-IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) GENE POLYMOR-
PHISM AND BKV ASSOCIATED HEMORRHAGIC CYSTITIS IN HEMATOPOI-
ETIC STEM CELL TRANSPLANT RECIPIENTS
Askar, M., Mossad, S., Zhang, A., Rybicki, L., Thomas, D., Tench, S.,
Copelan, E., Bolwell, B., Sobecks, R. Cleveland Clinic
Hemorrhagic cystitis (HC) is the most prevalent complication of
BK viruria after allogeneic hematopoietic stem cell transplantation
(HSCT) and is associated with significant morbidity and mortality.
However, why 40–50% of HSCT recipients with persistent viruria
never developHC remains unclear. Killer-immunoglobulin-like Re-
ceptor (KIR) gene polymorphism has been implicated in influencing
clinical outcomes of a number of viruses such as CMV, Hepatitis C,
and HIV.
Objective: To determine whether KIR gene polymorphisms has
a potential role in the development of BKV associated HC after
allogeneic HSCT.
Methods: We performed a retrospective 1:2 matched case-control
study of allogeneic HSCT recipients who underwent transplant at
our institution from 2000-2010. We performed KIR genotyping
for 32 cases with BKV associated HC and 64 matched controls with-
out HC. Two controls were selected for each case, and matched for
disease, preparative regimen, and development of acute GvHD prior
to HC. Recipient KIR genotyping was determined by PCR-rSSOP
(Luminex, One Lambda). Recipient KIR genotype and haplotypes
were assigned as described previously (Middleton andGonzelez, Im-
munology, 2010). The donor’s human leukocyte antigen (HLA) typ-
ing was reviewed from patient charts for determination of KIR
ligands. Conditional logistic regression analysis was used to assess
the association of KIR gene polymorphism and BKV associated
HC. Stepwise analysis using a variable entry criterion of P\ 0.10
and a variable retention criterion of P \ 0.05 was used to assess
multivariable risk factors.
Results:No significant association was identified at the 5% level of
significance between the development of HC and KIR genotypes,
Haplotypes (AA vs. Bx), number of activating receptors, presence
of any particular activating or inhibitory KIRs, or presence of any
cognate HLA ligands.
Conclusion: In contrast to the reported associations between KIR
gene polymorphism and different outcomes of other viruses, our
study does not support a role for KIR gene polymorphism in the
development of BKV associated HC.
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WHY WORK-UP REQUESTS FOR HSCT DONORS FAIL – REASONS AND
WAYS TO IMPROVE FROM A DONOR CENTER PERSPECTIVE
Mengling, T.1, Cotta, L.1, Schmidt, A.H.1, Ehninger, G.2 1DKMS
German Bone Marrow Donor Center, Tuebingen, Germany; 2University
Hospital Carl Gustav Carus, Dresden, Germany
Since 1992, DKMS German Bone Marrow Center has processed
28,672 work-up requests for hematopoietic stem cell donations.
4,328 requests (15.1%) were cancelled by the transplant centers for
patient-related reasons. Of the remaining, 22,840 (93.8%) requests
were successfully completed by collection and transplantation of a vi-
able stem cell product.
Since every work-up is a time and resource intensive process, it is
crucial to minimize the number of futile requests. Therefore, we
have assessed medical and non-medical conditions leading to donor
deferral or temporary unavailability, and identified donor subgroups
more likely to cancel their willingness late in the donor search pro-
cess. Due to the additional costs and loss of time, donors who did
S308 Poster Session IInot proceed during and after the medical clearance are of particular
interest.
324 donors contacted for work-up (1.3% of the non-cancelled re-
quests) were considered permanently unfit for donation (status DD,
donor deferred), the majority of them by the apheresis centers during
medical clearance. Only 22.8% could be identified by DKMS before
apheresis center clearing.
While 828 donors (3.45% of non-cancelled requests) were tempo-
rarily unavailable (status TU) for medical or non-medical reasons,
the transplant centers could be notified in 61% of those cases prior
to medical clearing. 323 donors contacted (1.3% of the non-can-
celled) withdrew their consent to donate (32.2% during or after
clearance).
We have analyzed demographic factors (age, gender, place of liv-
ing, ethnicity) to identify potential risk factors for failing work-ups.
It showed that 2.0% of female but only 1.1% of male donors with-
drew their consent to donate on the work-up level (p\0.001).While
the average donor age of all non-cancelled requests was 32.9 years, it
was 36.8 years for those donors who were permanently deferred for
medical reasons. Medical reasons included both medical findings
that were unknown to the donor before physical examination and
medical issues known to the donor that could not be covered during
confirmatory typing process. The latter category needs to be specif-
ically addressed to further improve the donor selection process.
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OUTCOMES OF A 1-DAY NONMYELOABLATIVE PREPARATIVE REGIMEN
FOR PRIMARY GRAFT FAILURE AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION
Kanda, J., Horwitz, M.E., Long, G.D., Gasparetto, C., Sullivan, K.M.,
Chute, J.P., Morris, A., Hennig, T., Chao, N.J., Rizzieri, D.A. Duke
University Medical Center, Durham, NC
Primary graft failure after allogeneic stem cell transplantation is
a life-threatening complication because of prolonged neutropenia af-
ter the initial transplantation. A shortened conditioning regimen fol-
lowed by re-transplantation may increase the chance of survival.
Here, we report 11 patients with a median age of 44 (range, 25-67)
years, who received a 1-day reduced-intensity preparative regimen
and subsequent re-transplantation for primary graft failure. The dis-
eases in these patients were as follows: acute myelogenous leukemia/
myelodysplastic syndromes in 6, myeloproliferative diseases in 3,
chronic lymphocytic leukemia in 1, and aplastic anemia in 1. All 11
patients experienced primary engraftment failure following a T-
cell depleted, fludarabine-based nonmyeloablative transplantation
from a haploidentical donor (n 5 6), a matched sibling donor (n 5
1), a matched unrelated donor (n 5 2), or after myeloablative trans-
plantation from dual umbilical cord blood units (n 5 2). The 1-day
preparative regimen for graft failure rescue consisted of 30 mg/m2
fludarabine, 2 g/m2 cyclophosphamide, 20 mg/body alemtuzumab,
and 200 cGy total body irradiation, all delivered 1 day prior to trans-
plantation. Five patients received grafts from the same haploidentical
donor; 5, from a different haploidentical donor; and 1, from the same
matched sibling donor. Out of the 11 patients, 9 engrafted. Of these,
one developed Grade II acute GVHD, and one, Grade I acute
GVHD. At present, 8 out of the 11 patients are alive with a median
follow-up of 9.2 (range, 2.3-28.8) months from the initial transplan-
tation and 7 are in remission. Three patients died, 1 due to infection
and 2 secondary to multi-organ failure. In conclusion, although the
number is small, this case-series suggest that our 1-day preparative
regimen is feasible, leads to successful engraftment in a high propor-
tion of patients, and might be appropriate for patients requiring
immediate re-transplantation after primary graft failure.425
REDUCED INTENSITY VERSUS STANDARD MYELOABLATIVE CONDITION-
ING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN SECOND COM-
PLETE REMISSION
Terwey, T.H.1, Hemmati, P.G.1, Vuong, L.G.1, le Coutre, P.1,
Massenkeil, G.2, D€orken, B.1, Arnold, R.1 1Charite - Universit€atsmedizin
Berlin, Berlin, Germany; 2City Hospital of G€utersloh, G€utersloh,
GermanyIntroduction:We have recently presented data for 93 patients (pts)
transplanted for AML in CR1 where we did not observe a significant
overall survival (OS) difference between reduced intensity (RIC) and
myeloablative conditioning (MAC) (5-yearOS 61% vs. 56%) despite
the fact that RIC pts were significantly older with higher hematopoi-
etic cell transplantation-specific comorbidity index scores (HCT-
CI) (Hemmati et al., Int JHematol. 2010, 91:436-45).Nowwe aimed
to determine whether RIC was similarly safe and effective when
administered in CR2.
Methods:We retrospectively analyzed 38 consecutive AMLpts who
were transplanted in CR2 between 1999 and 2008. 16 pts received
RIC (6x30 mg/m2 FLU, 4x4 mg/kg BU, 4x10 mg/kg ATG) and im-
munosuppression with CSA/MMF and 22 pts received MAC (6x2
Gy TBI and 2x60 mg/kg CY) and CSA/MTX. Donors were HLA-
matched related (5/16 vs. 7/22), -matched unrelated (7/16 vs. 12/
22) or -mismatched (4/16 vs. 3/22) and peripheral blood stem cells
(15/16 vs. 21/22) or bone marrow (1/16 vs. 1/22) were given. Pts
in the RIC group were significantly older (58 years (range: 47-69)
vs. 39 years (20-57), p\ 0.0001) and more pts were HCT-CI high
risk (7/16 vs. 2/22, p 5 0.02). All other patient and treatment
characteristics were similar.
Results: Median follow-up was 49 months (2-107). OS was signifi-
cantly inferior for RIC vs. MAC (multivariate HR 2.50, 95%CI:
1.03-6.11, p5 0.037) with projected OS rates at 1, 2 and 5 years be-
ing 35% vs. 71%, 28% vs. 67% and 28% vs. 52%. Trends for in-
creased cumulative incidence of non-relapse mortality (31% (19%
infection, 12% GVHD) vs. 19% (5% infection, 14% GVHD), p 5
0.3) and of relapse (50% vs. 29%, p 5 0.16) both contributed to
the inferior RIC results. Interestingly, the cumulative incidence of
NIH criteria acute (44% vs. 74%, p 5 0.033) and chronic GVHD
(25% vs. 71%, p 5 0.025) was significantly higher after MAC, sug-
gesting that the lower relapse rate after MAC was not only due to
the higher conditioning intensity but also due to a more potent
GVL effect.
Conclusions: Although our study population was small and subject
to various confounders the current data suggest that in contrast to
CR1 FLU/BU/ATG is not an optimal regimen for AML pts in
CR2 because non-relapse mortality remains substantial and relapse
rates are much higher than with MAC.With reference to the higher
incidence of GVHD after MAC we hypothesize that a modification
of the RIC regimen with better exploitation of the GVL effect may
be beneficial.426
MAJOR ABO MISMATCH INCREASES RED BLOOD CELL TRANSFUSION
REQUIREMENTS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANTATION USING TOTAL LYMPHOID IRRADIATION AND ANTI-
THYMOGLOBULIN CONDITIONING
Alimoghaddam, K.1, Weiss, S.2, Logan, A.3, Lowsky, R.3, Fontaine, M.2,
Miklos, D.3 1Tehran University of Medical Sciences, Tehran, Islamic Re-
public of Iran; 2Stanford School of Medicine, Palo Alto, CA; 3Stanford
School of Medicine, Palo Alto, CA
Introduction:The clinical impact of ABOmismatch between hema-
topoietic cell transplant (HCT) recipients and their donors remains
controversial. TLI/ATG is a reduced intensity conditioning regimen
associated with low rates of non-relapse mortality. Here, we report
the effects of ABOmismatch on neutrophil and platelet engraftment,
and on red blood cell (RBC) transfusion requirements after TLI/
ATG allo-HCT.
Material and Methods:We analyzed the outcomes of 266 patients
who underwent TLI-ATG conditioned allo-HCT from Jan 2005 to
July 2010, including 139 men and 127 women (median age 57). The
most common indications for HCT were acute leukemia (n 5 91)
and non-Hodgkin lymphoma (n 5 73). Cumulative RBC transfu-
sions through 100 days post-HCT, one year post-HCT, and last fol-
low-up were compared between ABO matched and mismatched
donor-recipient pairs by the Mann-Whitney test.
Results: ABO matched, major mismatched and bidirectionally mis-
matched donor-recipient pairs were observed in 141(53%), 54
(20.3%), and 20(7.5%) of cases. In this cohort following condition-
ing, 149 did not experience an absolute neutrophil count (NC) less
than 500/microliter, and 19 patients did not have NC count less
